[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Galus R, Włodarski P, Włodarski KH: Fluvastatin does not elevate periosteal osteogenesis induce by Moloney sarcoma virus (MSV) in mice. Pharmacol Rep; 2006 Jan-Feb;58(1):60-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluvastatin does not elevate periosteal osteogenesis induce by Moloney sarcoma virus (MSV) in mice.
  • Two groups were injected with Moloney-murine sarcoma virus (Mo-MSV) into right thighs to induce orthotopic bone formation.
  • [MeSH-major] Fatty Acids, Monounsaturated / pharmacology. Indoles / pharmacology. Osteogenesis / drug effects
  • [MeSH-minor] Alkaline Phosphatase / blood. Animals. Lipids / blood. Mice. Mice, Inbred Strains. Moloney murine sarcoma virus. Neoplasms / drug therapy. Periosteum / drug effects. Periosteum / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16531631.001).
  • [ISSN] 1734-1140
  • [Journal-full-title] Pharmacological reports : PR
  • [ISO-abbreviation] Pharmacol Rep
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Fatty Acids, Monounsaturated; 0 / Indoles; 0 / Lipids; 4L066368AS / fluvastatin; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


2. Revell MP, Deshmukh N, Grimer RJ, Carter SR, Tillman RM: Periosteal Osteosarcoma: A Review of 17 Cases with Mean Follow-up of 52 Months. Sarcoma; 2002;6(4):123-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periosteal Osteosarcoma: A Review of 17 Cases with Mean Follow-up of 52 Months.
  • PURPOSE: Periosteal osteosarcomas are rare cartilage-rich bone tumours characterized by a juxtacortical eccentric position and are normally regarded oncologically as of intermediate to high grade.Their low incidence is mirrored by a small number of reported cases in the world literature.
  • While there is general agreement that wide surgical excision is required, there is a paucity of evidence regarding adjuvant therapy.
  • Our policy was to use chemotherapy when the tumour showed any features of high grade.
  • DISCUSSION: Comparison of survival with existing studies is made to draw conclusions regarding future treatment of this condition in terms of surgical and adjuvant approaches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1976 May;37(5):2476-85 [1063059.001]
  • [Cites] Clin Orthop Relat Res. 1999 Jan;(358):8-14 [9973971.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(1):39-46 [11165128.001]
  • [Cites] Cancer. 1955 Sep-Oct;8(5):1060-9 [13261066.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1579-91 [1403038.001]
  • [Cites] Sarcoma. 1997;1(3-4):167-74 [18521220.001]
  • [Cites] J Bone Joint Surg Br. 1991 Sep;73(5):762-9 [1894662.001]
  • [Cites] Arch Orthop Trauma Surg. 1979 Jul 31;94(2):91-8 [289343.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] Clin Orthop Relat Res. 1987 Jun;(219):299-307 [3472700.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):165-71 [3965078.001]
  • [Cites] Semin Diagn Pathol. 1984 Aug;1(3):165-72 [6400634.001]
  • [Cites] J Bone Joint Surg Br. 1982;64(3):370-6 [7096408.001]
  • [Cites] Ital J Orthop Traumatol. 1976 Apr;2(1):23-35 [824226.001]
  • [Cites] J Bone Joint Surg Br. 1996 Jan;78(1):5-13 [8898118.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):1-13 [9006316.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):911-7 [9314869.001]
  • [Cites] J Bone Joint Surg Br. 1999 May;81(3):488-94 [10872373.001]
  • (PMID = 18521348.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395495
  •  go-up   go-down


3. Rajappa S, Menon PG, Sundaram S: Ewings sarcoma of the hand-a case report. J Hand Microsurg; 2010 Dec;2(2):82-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewings sarcoma of the hand-a case report.
  • Ewings sarcoma of the hand is relatively rare.
  • Ewings sarcoma can present with minimal pain and swelling of the affected digit.
  • Radiologically, Ewings sarcoma can present with a plethora of features from permeative bone destruction to expansile lesions with or without periosteal reaction.
  • This leads to starting of inappropriate treatment and delay in diagnosis.
  • He was started on anti-tuberculous treatment and did not respond to it.
  • Subsequent investigation in our centre which also included an open biopsy, confirmed the diagnosis of Ewings sarcoma.
  • He was treated with ray excision, and chemotherapy.
  • This would prevent delay in diagnosis of rare conditions like Ewings sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22282674.001).
  • [ISSN] 0974-6897
  • [Journal-full-title] Journal of hand and microsurgery
  • [ISO-abbreviation] J Hand Microsurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3122706
  • [Keywords] NOTNLM ; Dactylytis / Ewings sarcoma / Hand
  •  go-up   go-down


Advertisement
4. Gortzak Y, Lockwood GA, Mahendra A, Wang Y, Chung PW, Catton CN, O'Sullivan B, Deheshi BM, Wunder JS, Ferguson PC: Prediction of pathologic fracture risk of the femur after combined modality treatment of soft tissue sarcoma of the thigh. Cancer; 2010 Mar 15;116(6):1553-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of pathologic fracture risk of the femur after combined modality treatment of soft tissue sarcoma of the thigh.
  • BACKGROUND: The objective of the current study was to formulate a scoring system to enable decision making for prophylactic stabilization of the femur after surgical resection of a soft tissue sarcoma (STS) of the thigh.
  • METHODS: A logistic regression model was developed using patient variables collected from a prospectively collected database.
  • The study group included 22 patients who developed a radiation-related pathological fracture of the femur after surgery and radiotherapy for an STS of the thigh.
  • The control group of 79 patients received similar treatment but did not sustain a fracture.
  • No patients received chemotherapy.
  • The variables examined were age, gender, tumor size, radiation dose (low [50 grays (Gy)] vs high [> or = 60 Gy]), extent of periosteal stripping (<10 cm, 10-20 cm, and >20 cm), and thigh compartment involvement (posterior, adductor, anterior or other [ie, abductors and groin]).
  • The results of the current study suggest that it is possible to predict radiation-associated pathological fracture risk using patient and treatment variables with high sensitivity and specificity.
  • This would allow for the identification of high-risk patients and treatment with either close follow-up or prophylactic intramedullary nail stabilization.
  • [MeSH-major] Combined Modality Therapy / adverse effects. Femur. Fractures, Spontaneous / complications. Sarcoma / complications. Thigh

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20108335.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, Juergens H: Ewing's sarcoma family of tumors: current management. Oncologist; 2006 May;11(5):503-19
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ewing's sarcoma family of tumors: current management.
  • Ewing's sarcoma is the second most frequent primary bone cancer, with approximately 225 new cases diagnosed each year in patients less than 20 years of age in North America.
  • Pathognomonic translocations involving the ews gene on chromosome 22 and an ets-type gene, most commonly the fli1 gene on chromosome 11, are implicated in the great majority of cases.
  • Imaging reveals a technetium pyrophosphate avid lesion that, on plain radiograph, is destructive, diaphyseal and classically causes layered periosteal calcification.
  • Management, preferably at a specialist center with a multi-disciplinary team, includes both local control-either surgery, radiation or a combination-and systemic chemotherapy.
  • Chemotherapy includes cyclic combinations, incorporating vincristine, doxorubicin, cyclophosphamide, etoposide, ifosfamide and occasionally actinomycin D.
  • Studies incorporating intensive therapy followed by stem cell infusion show no clear benefit.
  • New approaches include anti-angiogenic therapy, particularly since vascular endothelial growth factor is an apparent downstream target of the ews-fli1 oncogene.
  • [MeSH-major] Bone Neoplasms / therapy. Sarcoma, Ewing / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Oncogene Proteins, Fusion / genetics. Oncogene Proteins, Fusion / metabolism. Proto-Oncogene Protein c-fli-1 / genetics. Proto-Oncogene Protein c-fli-1 / metabolism. RNA-Binding Protein EWS. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720851.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS
  • [Number-of-references] 157
  •  go-up   go-down


6. Boumdin H, el Quessar A, Chakir N, el Hassani MR, Jiddane M: [Primary Ewing's sarcoma of the cranial vault. Report of 2 cases]. J Neuroradiol; 2001 Sep;28(3):200-4
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary Ewing's sarcoma of the cranial vault. Report of 2 cases].
  • Primary Ewing sarcoma of the calvarial skull is very rare, found in less than 1% of the cases.
  • We report two cases of primary Ewing sarcoma of the skull (in 13- and 14-year-old boys.
  • The first tumor involved the right temporal region and exhibited unclear osteolytic appearance on skull x-rays while computed tomography showed an extraaxial enhanced mass and bone sclerosis with spiculated periosteal reaction.
  • Plain films demonstrated a large osteolysis and computed tomography revealed extensive bone destruction involving both the inner and outer tables.
  • Adjuvant chemotherapy was given and no recurrence or metastasis has occurred two years later.
  • [MeSH-major] Sarcoma, Ewing / diagnosis. Skull Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11894527.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Chen W, Zhu H, Zhang L, Li K, Su H, Jin C, Zhou K, Bai J, Wu F, Wang Z: Primary bone malignancy: effective treatment with high-intensity focused ultrasound ablation. Radiology; 2010 Jun;255(3):967-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone malignancy: effective treatment with high-intensity focused ultrasound ablation.
  • From December 1997 to November 2004, 80 patients with a primary bone malignancy-60 with stage IIb disease and 20 with stage III disease (Enneking staging system)-were treated with US-guided high-intensity focused ultrasound ablation.
  • High-intensity focused ultrasound ablation combined with chemotherapy was performed in 62 patients with osteosarcoma, one patient with periosteal osteosarcoma, and three patients with Ewing sarcoma.
  • The remaining 14 patients had chondrosarcoma, giant cell bone cancer, periosteal sarcoma, or an unknown malignancy and were treated with high-intensity focused ultrasound ablation only.
  • Magnetic resonance (MR) imaging or computed tomography (CT), and single photon emission computed tomography (SPECT) were used to assess tumor response.
  • RESULTS: High-intensity focused ultrasound ablation guided by real-time US was performed.
  • Among the patients with stage IIb disease, long-term survival rates were substantially improved in the 30 patients who received the full treatment-that is, complete high-intensity focused ultrasound and full cycles of chemotherapy-compared with the survival rates for the 24 patients who did not finish the chemotherapy cycles and the six patients who underwent partial ablation only.
  • [MeSH-major] Bone Neoplasms / therapy. Ultrasonic Therapy / methods. Ultrasonography, Interventional
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Prospective Studies. Survival Rate. Tomography, Emission-Computed, Single-Photon. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2010
  • (PMID = 20501734.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


8. Delepine F, Delepine G, Cohen C, Delepine N: [Periosteal Ewing's sarcoma]. Rev Chir Orthop Reparatrice Appar Mot; 2002 Apr;88(2):188-92
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Periosteal Ewing's sarcoma].
  • Periosteal Ewing's sarcoma is a histologically typical Ewing's sarcoma arising in the periosteum with no involvement of the medullary canal or cancellous bone.
  • We describe four cases in our experience and review the literature, recalling the usual computed tomography diagnostic criteria and the therapeutic consequences.
  • Prognosis of periosteal Ewing's sarcoma is generally better than for ordinary Ewing's sarcoma.
  • At surgical resection, cortical resection can be partial maintaining a continuous diaphysis; this should be examined as a possibility for young patients in order to avoid the problems encountered with massive reconstruction followed by chemotherapy.
  • [MeSH-major] Bone Neoplasms. Periosteum. Sarcoma, Ewing
  • [MeSH-minor] Adolescent. Child. Female. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11973551.001).
  • [ISSN] 0035-1040
  • [Journal-full-title] Revue de chirurgie orthopédique et réparatrice de l'appareil moteur
  • [ISO-abbreviation] Rev Chir Orthop Reparatrice Appar Mot
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 11
  •  go-up   go-down


9. Kopys-Wiszniewska I: [Evaluation of images of periosteum on computed tomography in children with malignant bone tumours before and after chemotherapy]. Med Wieku Rozwoj; 2008 Jan-Mar;12(1):463-76
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of images of periosteum on computed tomography in children with malignant bone tumours before and after chemotherapy].
  • AIM: to assess the value of different images of periosteal reaction on computed tomography (CT) in children with malignant bone tumours in determining the effectiveness of the chemotherapy.
  • To evaluate the prognostic value of particular symptoms of the periosteal reaction.
  • Osteogenic sarcoma (59 patients), Ewing's sarcoma/PNET (14 patients) and other mesenchymal tumours (7 patients) were diagnosed.
  • The assessment of the periosteum was carried out before and after preliminary chemotherapy.
  • Eleven symptoms of the periosteal reaction were distinguished:.
  • The kind of response to chemotherapy was determined on the basis of these symptoms relations.
  • RESULTS: the relationship of symptoms of the periosteal reaction and histopathological response to chemotherapy was determined.
  • Assessment of tumour reaction to chemotherapy based on own system of evaluation was in agreement with the histopathological results in 96.9% in the group of good responses (31/32), in 66.7% in group of medium responses (10/15) and in 87.9% in the group of poor responses (29/33), (dSomers coefficient 0.840, chi2 v=100.739 df=4 p<0.001).
  • The author's own scheme of evaluation of periosteal reactions on CT provides good correlation and concordance with the histopathological assessment of the kind of response to chemotherapy in children with malignant bone tumours.
  • 2. Analysis of manifestations of periosteal reaction on CT demonstrates full prognostic conformity of the so-called unfavourable symptoms to findings of the histopathological examination in the estimation of poor response.
  • 3. Favourable periosteal reactions are found in all types of response, but three of them, i.e. reduced number of periosteal proliferations, total reconstruction of the broken periosteum and total rebuilding of the Codman's triangle, show significant frequency only in cases of good response.
  • 4. Uncertain symptoms: unchanged periosteal thickness, lack of incorporation of spicules, decreased of number of unincorporated spicules, increased or unchanged size of unreactive (uncalcified and necrotic) areas - did not appear in cases of good response.
  • 5. Decreased size of the tumour (i.e. distance between periosteum and bone) appears in all types of response to chemotherapy and it cannot be regarded as a manifestation of good response.
  • 6. Own system of evaluation of tumour response to chemotherapy, based on the relationship manifestations of periosteal reaction is confirmed by statistical analysis.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / radiography. Osteosarcoma / radiography. Periosteum / drug effects. Periosteum / radiography
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Poland. Prognosis. Retrospective Studies. Sarcoma, Ewing / drug therapy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663266.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


10. Hatori M, Okada K, Nishida J, Kokubun S: Periosteal Ewing's sarcoma: radiological imaging and histological features. Arch Orthop Trauma Surg; 2001 Nov;121(10):594-7
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periosteal Ewing's sarcoma: radiological imaging and histological features.
  • Periosteal Ewing's sarcoma is very rare.
  • In this report, we describe three cases of periosteal Ewing's sarcoma, illustrating the principal clinical, radiographic, and histologic features.
  • Plain radiography showed a laminated periosteal reaction with a Codman's triangle over a subperiosteal soft-tissue mass or saucerization.
  • The unusual site of Ewing's sarcoma was clearly visualized by computed tomography (CT) and magnetic resonance imaging (MRI) and confirmed by histological examination.
  • Chemotherapy and/or irradiation was employed before and after wide excision.
  • [MeSH-major] Bone Neoplasms / diagnosis. Periosteum. Sarcoma, Ewing / diagnosis

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11768643.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Yoshida K, Kusuzaki K, Matsubara T, Matsumine A, Kumamoto T, Komada Y, Naka N, Uchida A: Periosteal Ewing's sarcoma treated by photodynamic therapy with acridine orange. Oncol Rep; 2005 Feb;13(2):279-82
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Periosteal Ewing's sarcoma treated by photodynamic therapy with acridine orange.
  • We recently encountered a very rare case of periosteal Ewing's sarcoma (PES), which was treated by surgery followed by photodynamic therapy using acridine orange with radiodynamic therapy.
  • Histopathological examination of biopsy specimens revealed a small round cell sarcoma suggestive of Ewing's sarcoma or PNET, and immunohistochemistry showed positive staining for MIC2.
  • Therefore, we administered preoperative chemotherapy, as a result of which the tumor shrank to 48% of its original volume.
  • With a view to preserve excellent shoulder and upper limb function, we attempted intralesional tumor resection supported by photodynamic therapy using acridine orange with radiodynamic therapy.
  • After surgery followed by postoperative chemotherapy, the patient has, until the time of writing, had no local tumor recurrence and no evidence of metastatic disease, and can move his shoulder fully and throw a ball well.
  • Since it has been reported that PES has a better prognosis and responsiveness to chemotherapy than intramedullary Ewing's sarcoma, we believe that such reduction surgery with photodynamic therapy might be the strategy of choice to obtain satisfactory limb function in cases of PES.
  • [MeSH-major] Bone Neoplasms / drug therapy. Humerus. Periosteum. Photochemotherapy / methods. Sarcoma, Ewing / drug therapy

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15643511.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] F30N4O6XVV / Acridine Orange
  •  go-up   go-down


12. Aymoré IL, Meohas W, Brito de Almeida AL, Proebstner D: Case report: Periosteal Ewing's sarcoma: case report and literature review. Clin Orthop Relat Res; 2005 May;(434):265-72
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: Periosteal Ewing's sarcoma: case report and literature review.
  • Ewing's sarcoma is a round-cell tumor that arises most often in a medullary cavity.
  • We report a new case of a 12-year-old boy with a periosteal Ewing's sarcoma, located in the femur, who was treated by cortical segmental resection associated with chemotherapy.
  • In reviewing the literature of 29 cases, it seems the prognosis is better in periosteal compared with intramedullary Ewing's sarcoma.
  • [MeSH-major] Bone Neoplasms / pathology. Femur. Limb Salvage / methods. Periosteum / pathology. Sarcoma, Ewing / pathology
  • [MeSH-minor] Biopsy, Needle. Bone Transplantation / methods. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging / methods. Male. Neoplasm Staging. Positron-Emission Tomography. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864063.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


13. Goto T, Hozumi T, Kondo T: [Ewing's sarcoma]. Gan To Kagaku Ryoho; 2004 Mar;31(3):346-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ewing's sarcoma].
  • Ewing's sarcomas account for 6.8% of all primary malignant bone tumors and are probably a neurogenic, undifferentiated, high-grade malignancy, which usually affects the bones of children 5-15 years of age.
  • When arising in the diaphysis of long bones, laminated, "onion-skin" periosteal reaction is seen.
  • Immunohistochemically, Ewing's sarcomas are positive for vimentin and MIC-2 gene product (CD99).
  • Because Ewing's sarcomas are chemosensitive and radiosensitive, they are treated by a combination of chemotherapy, surgery, and radiotherapy.
  • Neoadjuvant chemotherapy consists of preoperative chemotherapy and postoperative chemotherapy.
  • Preoperative chemotherapy aims at eradicating distant micrometastasis, reducing the primary tumor volume, and evaluating the efficacy of the chemotherapeutic agents.
  • Surgery is performed as a local treatment by excising the tumor using the wide procedure.
  • When surgery is performed without complete wide procedure, adjuvant radiotherapy is carried out to eradicate the residual tumor cells.
  • Postoperative chemotherapy aims to eradicate the distant micrometastasis.
  • Recently, myeloablative, high-dose chemotherapy followed by autologous bone marrow transplantation is being attempted for poor-prognosis patients and good results have been reported.
  • [MeSH-major] Bone Neoplasms. Sarcoma, Ewing
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Female. Humans. Magnetic Resonance Imaging. Male. Oncogene Proteins, Fusion / genetics. Proto-Oncogene Protein c-fli-1. RNA-Binding Protein EWS. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15045938.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS; 0 / Transcription Factors
  •  go-up   go-down


14. Song Y, Wang S, Chan M, Chandra B, Dhawan A, Song Y: Femoral fracture risk assessment after intensity modulated radiation therapy (IMRT) for the treatment of soft tissue sarcoma using a novel mathematical model. Conf Proc IEEE Eng Med Biol Soc; 2006;1:95-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Femoral fracture risk assessment after intensity modulated radiation therapy (IMRT) for the treatment of soft tissue sarcoma using a novel mathematical model.
  • Intensity modulated radiation therapy (IMRT) is often used for the treatment of soft tissue sarcoma.
  • Due to high radiation doses, many patients have high risk of suffering from a femoral bone fracture sometime following the IMRT treatment.
  • The most common type of radiation treatment-related fracture is a stress fracture.
  • The fracture risk rate may be as high as 24% in sarcoma patients who have undergone periosteal stripping and received chemotherapy.
  • Thus, it is necessary to be able to identify those patients with high risk for IMRT treatment-related bone fracture.
  • In this paper, we will first present IMRT treatment planning techniques.
  • We will then discuss how bone system changes their stiffness and how the fracture risk develops after a certain period of time post radiation treatment.
  • Finally, we will present our latest data on the femoral bone fracture risk factor assessment for patients with soft tissue sarcoma following IMRT treatment.
  • We have developed a novel mathematical model of trabecular bone composed of a disordered cubic network.
  • [MeSH-major] Femoral Fractures / etiology. Femoral Fractures / physiopathology. Fractures, Stress / etiology. Fractures, Stress / physiopathology. Models, Biological. Radiation Injuries / etiology. Radiation Injuries / physiopathology. Radiotherapy, Conformal / adverse effects. Sarcoma / radiotherapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17946381.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kimura K, Tatezaki S, Ishii T, Yonemoto T, Shigehara T, Takenouchi T: Hemiarthroplasty of the elbow with a vascularized fibular graft after excision of Ewing's sarcoma of the proximal ulna: a case report. Jpn J Clin Oncol; 2002 Oct;32(10):430-4
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemiarthroplasty of the elbow with a vascularized fibular graft after excision of Ewing's sarcoma of the proximal ulna: a case report.
  • We report an 8-year-old girl with a Ewing's sarcoma in the right proximal ulna.
  • The patient presented with pain in her right elbow, and plain radiographs showed destructive changes with a periosteal reaction in the proximal third of the ulna.
  • A biopsy confirmed the diagnosis of Ewing's sarcoma.
  • For preoperative chemotherapy, the patient received two courses of vincristine, doxorubicin and cyclophosphamide alternating with high-dose ifosfamide.
  • MRI and angiography demonstrated that the chemotherapy was effective and therefore the patient underwent wide local excision of the tumor and reconstruction of the elbow joint using a vascularized fibular graft.
  • After surgery, the patient received three courses of chemotherapy consisting of the same agents as those for the preoperative chemotherapy.
  • [MeSH-major] Arthroplasty / methods. Bone Neoplasms / surgery. Elbow Joint / surgery. Fibula / transplantation. Sarcoma, Ewing / surgery. Ulna

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12451042.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Hoshi M, Matsumoto S, Manabe J, Tanizawa T, Shigemitsu T, Takeuchi K, Kawaguchi N: Report of four cases with high-grade surface osteosarcoma. Jpn J Clin Oncol; 2006 Mar;36(3):180-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-grade surface osteosarcoma is the rarest of the three types of surface osteosarcoma.
  • Four cases with high-grade surface osteosarcoma arising from the distal femur and tibia are reported in this study.
  • Radiologically, three cases presented characteristic appearances suggesting high-grade bone-forming sarcoma arising from the bone surface; however, one case was similar to other juxtacortical lesions such as periosteal and parosteal osteosarcoma, which typically have a better prognosis than high-grade surface osteosarcoma.
  • Therefore, all cases underwent biopsy to determine a definitive diagnosis.
  • Our strategy of treatment for high-grade surface osteosarcoma was a combination of wide resection and pre-/post-operative chemotherapy, equivalent to the treatment for conventional intramedullary osteosarcoma.
  • At the last follow-up, two cases were still undergoing chemotherapy, one case was continuously disease free during the follow-up period of 81 months, and one patient was living with no evidence of disease 60 months after surgery.
  • The aim of this study is to report the clinical information, oncological outcome and appropriate treatment for high-grade surface osteosarcoma.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Tibia / surgery. Tomography, X-Ray Computed. Treatment Outcome. Turner Syndrome / complications

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533804.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


17. Blaes AH, Lindgren B, Mulrooney DA, Willson L, Cho LC: Pathologic femur fractures after limb-sparing treatment of soft-tissue sarcomas. J Cancer Surviv; 2010 Dec;4(4):399-404
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic femur fractures after limb-sparing treatment of soft-tissue sarcomas.
  • INTRODUCTION: Local control for sarcomas of the long bones includes limb sparing surgery and radiotherapy.
  • METHODS: Patients treated for a soft tissue sarcoma of the thigh with limb-sparing surgery and radiation therapy between 1986 and 2000 at the University of Minnesota Masonic Cancer Center (n=89) were identified.
  • Demographic, tumor, and treatment characteristics were abstracted from the medical record.
  • Significant risk factors included periosteal stripping (p=0.006), anterior compartment location (p=0.022), and having 100% of the femoral circumference irradiated (p=0.018).
  • Taking into account time to fracture using Kaplan Meier and log rank tests, these same predictors were identified.
  • Older age, female sex, use of chemotherapy, and timing of radiation were not predictive of femoral fracture.
  • CONCLUSION: Anterior tumor location, periosteal stripping, and radiation to 100% of the femur circumference are associated with femoral fracture.
  • IMPLICATIONS FOR CANCER SURVIVORS: Survivors of soft tissue sarcomas of the femur may be at risk for the development of femur fractures and warrant close observation.
  • [MeSH-major] Bone Neoplasms / therapy. Femoral Fractures / etiology. Sarcoma / complications. Sarcoma / therapy. Soft Tissue Neoplasms / complications. Soft Tissue Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2005 Nov 23;294(20):2587-93 [16304072.001]
  • [Cites] Int J Clin Oncol. 2003 Oct;8(5):336-9 [14586762.001]
  • [Cites] J Bone Joint Surg Am. 2005 Feb;87(2):315-9 [15687153.001]
  • [Cites] Acta Oncol. 1987;26(6):463-5 [3446245.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):265-74 [15337565.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):969-76 [7607971.001]
  • [Cites] Cancer. 1995 May 1;75(9):2299-306 [7712441.001]
  • [Cites] Clin Orthop Relat Res. 1991 Oct;(271):265-71 [1914305.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):977-85 [7607972.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):61-6 [10219795.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 2004 Sep;33(9):457-60; discussion 460 [15509111.001]
  • [Cites] Radiology. 1975 Dec;117(3 Pt 1):677-85 [1188119.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2356-65 [9635528.001]
  • [Cites] Clin Orthop Relat Res. 2001 Aug;(389):165-72 [11501806.001]
  • [Cites] Cancer. 2010 Mar 15;116(6):1553-9 [20108335.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2455-61 [17036354.001]
  • [Cites] Am J Physiol. 1953 Apr;173(1):115-9 [13050772.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2006;1:95-8 [17946381.001]
  • [Cites] CRC Crit Rev Diagn Imaging. 1980 Jan;12 (3):225-43 [6985580.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):598-602 [17183556.001]
  • (PMID = 20827514.001).
  • [ISSN] 1932-2267
  • [Journal-full-title] Journal of cancer survivorship : research and practice
  • [ISO-abbreviation] J Cancer Surviv
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Asavamongkolkul A, Waikakul S, Phimolsarnti R, Kiatisevi P, Wangsaturaka P: Endoprosthetic reconstruction for malignant bone and soft-tissue tumors. J Med Assoc Thai; 2007 Apr;90(4):706-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoprosthetic reconstruction for malignant bone and soft-tissue tumors.
  • BACKGROUND: Nowadays, the results of the management of malignant bone and soft-tissue tumors have been dramatically improved because of the advance in imaging, chemotherapy, radiation therapy, and surgical techniques.
  • Patients can have longer survival times with limb-salvage surgery.
  • OBJECTIVE: To report the preliminary results of 32 endoprosthetic reconstructions following malignant bone and soft-tissue tumor resection.
  • MATERIAL AND METHOD: Since September 1988, the authors have performed 188 limb-salvage surgical operations for the treatment of musculoskeletal tumors at Siriraj Hospital.
  • From March 1994 to July 2006, 32 endoprosthetic reconstructions were performed on 30 patients following malignant bone or soft-tissue tumor removal.
  • There were 16 males and 14 females with a mean age of 28 years (range 10-73).
  • The diagnosis was conventional osteosarcoma in 16 patients, parosteal osteosarcoma in two patients, chondrosarcoma in two patients, leiomyosarcoma in two patients, failed allograft in two patients and one patient each of periosteal osteosarcoma, Ewing's sarcoma, Gorham's disease, synovial sarcoma, malignant fibrous histiocytoma, metastatic renal cell carcinoma, and prosthetic loosening.
  • Wide excision was performed with a mean length of 18.5 cm (range 10-41).
  • Five proximal femurs, 17 distal femurs, 1 total femur 3 proximal tibias, 1 intercalary tibia, 4 proximal humerus and 1 distal humerus were used for reconstruction.
  • RESULTS: The mean follow-up time was 26 months (range 6-128.7).
  • CONCLUSION: Endoprosthetic reconstruction could yield satisfactory results as a wide excision and limb-salvage for patients with malignant bone and soft-tissue tumors.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage. Osteosarcoma / surgery. Sarcoma, Ewing / surgery. Soft Tissue Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487125.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


19. Kim S, Lee S, Arsenault DA, Strijbosch RA, Shamberger RC, Puder M: Pediatric rib lesions: a 13-year experience. J Pediatr Surg; 2008 Oct;43(10):1781-5
MedlinePlus Health Information. consumer health - Bone Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient's diagnosis, sex, symptoms and their duration, radiologic evaluation, biopsy status, surgical procedure, and follow-up were assessed.
  • Within the benign cohort of 16 patients, there were 6 osteochondromas, 4 aneurysmal bone cysts, and 2 fibrous dysplasias as well as 1 of each of the following: enchondroma, periosteal chondroma, eosinophilic granuloma, and chondrophyte.
  • Within the malignant cohort of 17 patients, 13 were diagnosed with Ewing's sarcoma, 3 with osteogenic sarcoma, and 1 with chondrosarcoma.
  • Therefore, proper diagnosis and expeditious treatment are critical.
  • [MeSH-minor] Adolescent. Biopsy. Bone Cysts, Aneurysmal / diagnosis. Bone Cysts, Aneurysmal / epidemiology. Bone Cysts, Aneurysmal / pathology. Bone Cysts, Aneurysmal / surgery. Bone Neoplasms / diagnosis. Bone Neoplasms / drug therapy. Bone Neoplasms / epidemiology. Bone Neoplasms / pathology. Bone Neoplasms / surgery. Boston / epidemiology. Child. Child, Preschool. Chondrosarcoma / diagnosis. Chondrosarcoma / drug therapy. Chondrosarcoma / epidemiology. Chondrosarcoma / pathology. Chondrosarcoma / surgery. Cohort Studies. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Male. Osteochondroma / diagnosis. Osteochondroma / epidemiology. Osteochondroma / pathology. Osteochondroma / surgery. Osteosarcoma / diagnosis. Osteosarcoma / drug therapy. Osteosarcoma / epidemiology. Osteosarcoma / pathology. Osteosarcoma / surgery. Retrospective Studies. Sarcoma, Ewing / diagnosis. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / epidemiology. Sarcoma, Ewing / pathology. Sarcoma, Ewing / surgery. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926207.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Castro JA, Hernández M, Sierra AC, Méndez JM, Macías C CR: [Distal tibial reconstruction and ankle arthrodesis in osteosarcoma (salvage technique). A case presentation]. Acta Ortop Mex; 2007 Sep-Oct;21(5):289-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distal tibial reconstruction and ankle arthrodesis in osteosarcoma (salvage technique). A case presentation].
  • [Transliterated title] Reconstrucción de tibia distal y artrodesis de tobillo en osteosarcoma (cirugía de salvamento). Presentación de un caso.
  • Treatment of bone sarcomas is aimed in healing and secondarily rescuing the limb.
  • With the use of chemotherapy, radiation therapy, new prostheses and availability of graft, now most tumors can be resected, reducing functional deficit.
  • OBJECTIVE: To present a surgical option in management of osteosarcoma of distal tibia.
  • CASE REPORT: Fifteen year-old man, starting in April 2003 with a mass in the left ankle area.
  • November 2003 the physical exam: limping by left lower limb, with a tumor in the posteromedial ankle surface (3 x 2 cm), hard, not movable, regular edges, painful on palpation, Radiographic observations (November 2003), showed blastic oval stone image (4 x 3.5 cm) with expanded posterior and medial cortices with periosteal reaction.
  • The final histological report was positive to osteogenic sarcoma.
  • The patient received 11 sessions of chemotherapy.
  • The reconstruction of the distal tibia and arthrodesis with autologous graft from the fibula, heterologous graft and stabilization with transcalcaneal nail, was done in March 2005.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bone Nails. Chemotherapy, Adjuvant. Chondroblastoma / diagnosis. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnostic Errors. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fibula / transplantation. Humans. Ifosfamide / administration & dosage. Internal Fixators. Male. Transplantation, Autologous

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18159919.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


21. Vasanawala MS, Wang Y, Quon A, Gambhir SS: F-18 fluorodeoxyglucose PET/CT as an imaging tool for staging and restaging cutaneous angiosarcoma of the scalp. Clin Nucl Med; 2006 Sep;31(9):534-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It differs from other soft tissue sarcomas in that the size of the lesion at presentation instead of tumor grade is the important prognostic factor.
  • Optimal treatment is yet to be determined.
  • Wide-margin complete excision with postoperative radiotherapy has been the most effective therapy.
  • Chemotherapy and gene therapy have been used with some success.
  • Local extent is critical in surgical planning, especially in the head and face, and is difficult to determine accurately with clinical examination and morphologic imaging tools.
  • PET/CT imaging with F-18 2-fluoro-2-deoxyglucose (F-18 FDG) not only showed avid FDG uptake by an angiosarcoma (SUVmax = 10.7), but also simultaneously showed local extension of multifocal lesions with periosteal involvement and excluded metastatic abdominal nodal disease.
  • PET/CT imaging after chemotherapy and before radiation therapy showed complete resolution of FDG uptake in the scalp and osseous lesions.
  • Evaluation of more cases of this subset of soft tissue sarcoma with FDG PET/CT may suggest a possible role in not only staging angiosarcomas to determine the extent of local as well as distant disease, but also to potentially help determine response to therapy and early recognition of local or distant recurrence.
  • [MeSH-major] Fluorodeoxyglucose F18. Hemangiosarcoma / diagnosis. Hemangiosarcoma / radionuclide imaging. Neoplasm Staging / methods. Positron-Emission Tomography / methods. Radiopharmaceuticals. Scalp / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / radionuclide imaging. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921276.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


22. Okada K, Hasegawa T, Nishida J, Ogose A, Tajino T, Osanai T, Yanagisawa M, Hatori M: Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases--an experience in northern Japan. Ann Surg Oncol; 2004 Nov;11(11):998-1004
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common location was the distal femur (n = 13), followed by the pelvis (n = 10), proximal femur (n = 9), and proximal fibula (n = 6).
  • On radiographs, an osteolytic appearance without periosteal reactions was a common and characteristic feature.
  • Fourteen cases (22%) were secondary; postradiation osteosarcoma was most common in these patients, but there was no Paget's sarcoma.
  • Preoperative chemotherapy was given to 22 patients, but the effect was poor in 18 cases (82%).
  • Current systemic chemotherapy is not effective for this age group.
  • Alternative treatment strategies should be considered.
  • [MeSH-minor] Age of Onset. Aged. Combined Modality Therapy. Female. Humans. Japan. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Metastasis. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15525829.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Delépine F, Delépine G, Belarbi L, Markowska B, Alkallaf S, Cornille H, Delépine N: [Diagnosis and treatment of malignant bone fibrohistiocytoma]. Ann Med Interne (Paris); 2001 Nov;152(7):437-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of malignant bone fibrohistiocytoma].
  • [Transliterated title] Diagnostic et traitement des histiocytofibromes malins de l'os.
  • Malignant fibrous histiocytoma (MFH) and giant cells sarcoma arise from fibrous tissue and histiocytic cells evenly distributed in all age group, except children much less common than osteosarcoma and chondrosarcoma.
  • Medical imaging shows a purely osteolytic tumor centrally or eccentrically located, ill defined with a permeative or even moth eaten patterns.
  • Periosteal reaction is scarce or absent.
  • Outcome was historically better than those of osteosarcoma but hangs on the grading of tumors; low grade sarcoma have a regional evolution while high grade malignant histiocytofibroma are threatened with metastases.
  • Therapy must be adapted to the histological grading and the extent of the illness.
  • High grade MFH are preferentially treated by a comprehensive multidisciplinary approach with preoperative chemotherapy including high dose methotrexate, wide resection and postoperative chemotherapy.
  • With such a treatment, nearly 80% of patients seen with localized tumor of the limb can be cured and keep a functional limb.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Female. Humans. Limb Salvage. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11965084.001).
  • [ISSN] 0003-410X
  • [Journal-full-title] Annales de médecine interne
  • [ISO-abbreviation] Ann Med Interne (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. McTiernan A, Whelan JS: A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma. Sarcoma; 2004;8(2-3):71-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II Study of Docetaxel for the Treatment of Recurrent Osteosarcoma.
  • Diagnosis was: conventional osteosarcoma, 12 patients; periosteal osteosarcoma, one patient; and malignant fibrous histiocytoma of bone, one patient.
  • Initial chemotherapy had been with doxorubicin and cisplatin in 10 patients, and multiagent regimens in four.
  • Nine had been treated with second line chemotherapy before receiving docetaxel.
  • The principle toxicity was haematological, with a median neutrophil count of 0.9 (range 0-9.6).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3016-24 [12837811.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] J Natl Cancer Inst. 1991 Feb 20;83(4):288-91 [1671606.001]
  • [Cites] J Natl Cancer Inst. 1991 Dec 18;83(24):1797-805 [1683908.001]
  • [Cites] Sarcoma. 2003;7(1):13-7 [18521364.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):733-7 [10213206.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2341-54 [10561296.001]
  • [Cites] Ann Intern Med. 1989 Aug 15;111(4):273-9 [2569287.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):1016-9 [7547214.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1084-93 [7850705.001]
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):132-9 [10776972.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2081-6 [10811673.001]
  • [Cites] Clin Orthop Relat Res. 2001 Feb;(383):259-67 [11210963.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):604-10 [11237379.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2001 May;23(3):190-2 [11783082.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):710-5 [12586810.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(4):488-94 [12751380.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):380-3 [7914428.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):539-42 [7918126.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):384-8 [8094466.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):741-4 [8756366.001]
  • [Cites] Am J Clin Oncol. 1996 Dec;19(6):574-6 [8931674.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):750-8 [9053501.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1071-9 [9060547.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1538-43 [9193350.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):911-7 [9314869.001]
  • [Cites] J Chemother. 1998 Feb;10(1):69-76 [9531078.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2452-8 [9667263.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Jul;25(7):539-42 [12847320.001]
  • (PMID = 18521398.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2395610
  •  go-up   go-down






Advertisement